
Quarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Market Cap 2011-2026 | CALT
As of March 25, 2026 Calliditas Therapeutics AB (publ) has a market cap of $ 2.03 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 966 M | 606 M | - | - | 106 M | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 966 M | 106 M | 559 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | ||
|
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | ||
|
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | ||
|
Aurora Cannabis
ACB
|
915 M | $ 3.43 | 3.31 % | $ 86.3 M | ||
|
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | ||
|
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B | ||
|
Pacira BioSciences
PCRX
|
1.18 B | $ 23.16 | -0.19 % | $ 1.07 B | ||
|
Cronos Group
CRON
|
3.63 B | $ 2.64 | 2.13 % | $ 1.34 B | ||
|
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
139 M | $ 8.36 | 4.3 % | $ 428 M | ||
|
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M | ||
|
Perrigo Company plc
PRGO
|
1.96 B | $ 9.84 | 2.07 % | $ 1.36 B | ||
|
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.03 | -3.19 % | $ 42.6 M | ||
|
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | ||
|
Rockwell Medical
RMTI
|
35.5 M | $ 1.08 | 4.37 % | $ 25.2 M | ||
|
Bausch Health Companies
BHC
|
3.38 B | $ 5.2 | 4.0 % | $ 1.9 B | ||
|
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | ||
|
Solid Biosciences
SLDB
|
623 M | $ 7.1 | 6.26 % | $ 621 M | ||
|
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | ||
|
Sundial Growers
SNDL
|
889 K | $ 1.4 | 1.82 % | $ 3.37 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.34 | - | $ 2.9 M | ||
|
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | ||
|
Evolus
EOLS
|
271 M | $ 4.44 | 0.23 % | $ 286 M | ||
|
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | ||
|
Tilray
TLRY
|
1.19 B | $ 7.02 | 5.45 % | $ 4.34 B | ||
|
Relmada Therapeutics
RLMD
|
247 M | $ 6.43 | 5.41 % | $ 254 M | ||
|
OrganiGram Holdings
OGI
|
382 M | $ 1.39 | 3.84 % | $ 402 M | ||
|
SCYNEXIS
SCYX
|
37.9 M | $ 0.92 | 2.51 % | $ 45.9 M | ||
|
Jupiter Wellness
JUPW
|
82.8 M | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
4.54 M | $ 0.59 | 3.79 % | $ 10.3 M | ||
|
Veru
VERU
|
108 M | $ 2.3 | 0.44 % | $ 310 M | ||
|
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | ||
|
Harrow Health
HROW
|
1.93 B | $ 36.09 | 2.53 % | $ 1.33 B | ||
|
Viatris
VTRS
|
18.4 B | $ 13.59 | 1.72 % | $ 16.3 B | ||
|
Organogenesis Holdings
ORGO
|
415 M | $ 2.49 | 3.31 % | $ 328 M | ||
|
Canopy Growth Corporation
CGC
|
142 M | $ 1.0 | 4.19 % | $ 108 M | ||
|
cbdMD
YCBD
|
1.68 M | $ 0.79 | 2.82 % | $ 3.41 M | ||
|
Assertio Holdings
ASRT
|
75.4 M | $ 16.81 | 1.82 % | $ 108 M | ||
|
TherapeuticsMD
TXMD
|
23.9 M | $ 2.28 | -0.44 % | $ 23.8 M | ||
|
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | ||
|
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M |